NCT06638034 Diagnosis of Metastatic Tumors on 68Ga-FAPI-RGD PET-CT and Radioligand Therapy With 177Lu-FAPI-RGD
| NCT ID | NCT06638034 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Peking Union Medical College Hospital |
| Condition | FAP- Expressing Positive Tumors |
| Study Type | INTERVENTIONAL |
| Enrollment | 15 participants |
| Start Date | 2024-05-01 |
| Primary Completion | 2025-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 15 participants in total. It began in 2024-05-01 with a primary completion date of 2025-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
FAP and RGD are overexpressed in many tumor tissues. This study is intended to conduct preliminary clinical transformation and internal irradiation dosimetry research on 177Lu-FAPI-RGD--a new dual-targeted 177Lu therapeutic drug for the first time in the world.
Eligibility Criteria
Inclusion Criteria: * confirmed treated or untreated metastatic tumors patients; * 68Ga-FAPI PET/CT and 18F-FDG PET/CT within two weeks; * signed written consent. Exclusion Criteria: * pregnancy; * breastfeeding; * any medical condition that in the opinion of the investigator may significantly interfere with study compliance
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06638034 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying FAP- Expressing Positive Tumors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06638034 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06638034 currently recruiting?
Yes, NCT06638034 is actively recruiting participants. Contact the research team at 13611093752@163.com for enrollment information.
Where is the NCT06638034 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06638034 clinical trial?
NCT06638034 is sponsored by Peking Union Medical College Hospital. The trial plans to enroll 15 participants.